With $1.2 billion on the line and a freshman course in chemistry under his belt, a juror on Wednesday derailed a two-month patent trial over pioneering DNA research.
After six days of deliberations, the jury said it was hopelessly deadlocked at 8-1 in favor of the University of California, which had sued Genentech Inc. for infringing a lucrative human growth hormone patent with widespread medical applications. Unlike state civil trials, where a 9-3 jury verdict carries the day, federal courts require unanimous verdicts — unless the parties agree otherwise.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
